Silvio Danese

Research interests

Publications

• IL-12 and IL-23 pathway inhibition in inflammatory bowel disease

  Nature Reviews Gastroenterology & Hepatology · 2023 · https://doi.org/10.1038/s41575-023-00768-1

• Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00061-2

• Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease

  Nature Reviews Gastroenterology & Hepatology · 2022 · https://doi.org/10.1038/s41575-021-00574-7

• Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)00581-5

• Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)00467-6

• Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)00466-4

• Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

  Gastroenterology · 2022 · https://doi.org/10.1053/j.gastro.2022.01.047

• STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

  Gastroenterology · 2021 · https://doi.org/10.1053/j.gastro.2020.12.031

• Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment

  Alimentary Pharmacology & Therapeutics · 2021 · https://doi.org/10.1111/apt.16712

• Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD

  Gastroenterology · 2021 · https://doi.org/10.1053/j.gastro.2020.10.065

• Ulcerative colitis

  Nature Reviews Disease Primers · 2020 · https://doi.org/10.1038/s41572-020-0205-x

• Crohn’s disease

  Nature Reviews Disease Primers · 2020 · https://doi.org/10.1038/s41572-020-0156-2

• Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting

  Gastroenterology · 2020 · https://doi.org/10.1053/j.gastro.2020.04.002

• Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1900750

• Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme

  Alimentary Pharmacology & Therapeutics · 2019 · https://doi.org/10.1111/apt.15514

• Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1606910

• Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)31203-x

• Development of an index to define overall disease severity in IBD

  Gut · 2016 · https://doi.org/10.1136/gutjnl-2016-312648

• ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update

  Journal of Crohn s and Colitis · 2016 · https://doi.org/10.1093/ecco-jcc/jjw198

• Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions

  Clinical Gastroenterology and Hepatology · 2015 · https://doi.org/10.1016/j.cgh.2015.06.001

• Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

  The American Journal of Gastroenterology · 2015 · https://doi.org/10.1038/ajg.2015.233

• Development of the Lémann Index to Assess Digestive Tract Damage in Patients With Crohn's Disease

  Gastroenterology · 2014 · https://doi.org/10.1053/j.gastro.2014.09.015

• Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study

  Gut · 2013 · https://doi.org/10.1136/gutjnl-2012-304258

• Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines

  Journal of Crohn s and Colitis · 2013 · https://doi.org/10.1016/j.crohns.2013.02.020

• Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1215734

• Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project

  Gut · 2012 · https://doi.org/10.1136/gutjnl-2011-300777

• Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations

  Journal of Crohn s and Colitis · 2012 · https://doi.org/10.1016/j.crohns.2012.09.005

• Development of the Crohnʼs disease digestive damage score, the Lémann score

  Inflammatory Bowel Diseases · 2010 · https://doi.org/10.1002/ibd.21506

• VEGF-A Links Angiogenesis and Inflammation in Inflammatory Bowel Disease Pathogenesis

  Gastroenterology · 2008 · https://doi.org/10.1053/j.gastro.2008.09.064

• TNF-α Blockade Down-Regulates the CD40/CD40L Pathway in the Mucosal Microcirculation: A Novel Anti-Inflammatory Mechanism of Infliximab in Crohn’s Disease

  The Journal of Immunology · 2006 · https://doi.org/10.4049/jimmunol.176.4.2617

Current projects

No projects listed.